Anavex Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement
Anavex Life Sciences has filed its delayed 2026 quarterly reports, removing a Nasdaq listing compliance risk and keeping AVXL on the Global Select Market.
Rhea-AI Summary
Anavex Life Sciences (AVXL) has regained compliance with Nasdaq's periodic filing requirement, ensuring continued listing of its common stock.
The company received confirmation from Nasdaq that it now complies with Listing Rule 5250(c)(1), which requires timely filing of all periodic reports with the SEC. Anavex filed its outstanding Form 10-Qs for the second and third fiscal quarters of 2026 on August 28, 2026. With these submissions, the company is in compliance with all Nasdaq listing standards and its shares will continue to trade on the Nasdaq Global Select Market under the ticker AVXL.
Positive
- Nasdaq compliance restored after filing outstanding Q2 and Q3 2026 Form 10-Qs on August 28, 2026
- Continued Nasdaq Global Select Market listing for AVXL common stock with all listing standards met
Negative
- Previous delay in SEC filings highlighted by the need to file outstanding Form 10-Qs for two 2026 quarters
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 25 | Q3 earnings report | Positive | +14.5% | Q3 results included $7.8 million net income and a clinical program update |
| Aug 17 | Stockholder letter | Positive | -0.3% | Stockholder letter sought support for six director nominees |
| Aug 11 | Proxy materials | Positive | +3.5% | Definitive proxy materials disclosed Nasdaq delinquency and meeting details |
| Aug 03 | Board refresh plans | Positive | +7.3% | Company announced board refresh plans to oversee clinical progress |
| Jul 30 | Q2 earnings report | Positive | +8.4% | Preliminary loss narrowed and a Nasdaq compliance plan was submitted |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Four of five recent news events had positive 24-hour reactions, while the August 17 stockholder-letter event diverged with a -0.31% reaction.
Key Terms
nasdaq listing rule 5250(c)(1) regulatory
form 10-q regulatory
cns medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Anavex Life Sciences is Pleased to Regain Full Compliance with Nasdaq, Continues to Execute on Clinical Development Strategy and Advance all Three Core Indications Forward
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (“CNS”) diseases with high unmet medical needs, today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires Nasdaq-listed companies to file all required periodic filings with the Securities and Exchange Commission (“SEC”).
On August 28, 2026, the Company filed its outstanding Form 10-Q filings for the second and third fiscal quarters of 2026 with the SEC. The Company is now in compliance with all Nasdaq listing standards, and its common stock will continue to trade on the Nasdaq Global Select Market under the ticker "AVXL."
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded clinical stage biopharmaceutical company engaged in the development of novel therapeutics for the treatment of central nervous system (“CNS”) diseases with high unmet medical need. Further information is available at www.anavex.com.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements relating to the Company’s ability to continue trading on the Nasdaq Global Select Market. These statements are based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such forward-looking statements due to various factors, including, but not limited to, risks related to the Company’s ability to maintain compliance with the Nasdaq Listing Rules; and other risks and uncertainties set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025, filed with the Securities and Exchange Commission (“SEC”) on November 25, 2025, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2025, filed with the SEC on February 9, 2026, the Company’s Form 10-K/A for the fiscal year ended September 30, 2025, filed with the SEC on August 28, 2026, the Company’s Form 10-Q/A for the quarterly period ended December 31, 2025, filed with the SEC on August 28, 2026, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, filed with the SEC on August 28, 2026, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 28, 2026, and subsequent filings and furnishings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof except as required by law.
Investor Relations & Media Contact:
SCR Partners, LLC
Alex Arzeno
Tel: 203-550-3972
Email: alex@scr-ir.com
Tripp Sullivan
Tel: 615-942-7077
Email: tsullivan@scr-ir.com
Company Contact:
Sandra Boenisch
Principal Financial Officer
Anavex Life Sciences Corp.
Tel: 1-844-689-3939
Email: ir@anavexcorp.com
